Reading LYEL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LYEL free→Reading LYEL? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track LYEL free→QuarterlyIQ Insights · LYEL
Material updates from SEC filings (8-K, 10-Q, 10-K) ranked by impact, with no firehose noise.
Results of Operations and Financial Condition. On May 6, 2026, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or other…
Results of Operations and Financial Condition. On March 12, 2026, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers . On March 6, 2026, the Board of Directors of Lyell Immunopharma, Inc. (the “Company”) approved the appointment of Smital Shah as the Company’s Chief Financial and Business Officer and principal financial officer, effective March 9, 2026. Lynn Seely, M.D., the Company’s President and Chief Executive Officer, previously served as interim principal fi…
Results of Operations and Financial Condition. On November 12, 2025, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”)…
and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act, except as expressly set forth by specific reference in such filing. Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meani…
Entry into a Material Definitive Agreement. On November 6, 2025 (the “Effective Date”), Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), entered into an Exclusive License Agreement (the “License Agreement”) with Innovative Cellular Therapeutics Holdings Limited, a Cayman Island exempted company incorporated with limited liability (“ICT Holdings”), and Innovative Cellular Therapeutics, Inc., a Delaware corporation (“ICT” and together with ICT Holdings, the “ICT Group”). Under…
of Form 8-K, is hereby incorporated by reference herein. The offer and sale of the securities issuable under the License Agreement are being made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”), and corresponding provisions of state securities or “blue sky” laws. The securities issuable under the License Agreement have not been registered under the Securities Act or any state securities laws and may not be offered or so…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On October 31, 2025, the Board of Directors of Lyell Immunopharma, Inc. (the “Company”) appointed Lynn Seely, M.D., the Company’s President, Chief Executive Officer and principal executive officer and a director of the Company, as the Company’s interim principal financial officer, and appointed Veronica Sanchez Bulis, the Company’s Vice President,…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On September 15, 2025, Charles Newton notified Lyell Immunopharma, Inc. (the “Company”) of his decision to resign from his position as the Chief Financial Officer and principal financial and accounting officer of the Company, effective October 31, 2025 (the “Resignation Date”). There were no disagreements between Mr. Newton and the Company. The Com…
Results of Operations and Financial Condition. On August 12, 2025, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or ot…
The Company expects to use the net proceeds from the Private Placement, together with the Company’s existing cash, cash equivalents, and marketable securities, to fund two pivotal-stage clinical trials of LYL314, as well as for working capital and other general corporate purposes. The securities described above under
Entry into a Material Definitive Agreement. On July 24, 2025, Lyell Immunopharma, Inc., a Delaware corporation (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain institutional and other accredited investors (the “Purchasers”), pursuant to which the Company agreed to sell and issue shares of the Company’s common stock, par value $0.0001 (“Common Stock”), and, if applicable, pre-funded warrants to purchase Common Stock, in up to two or more clo…
is furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act. The information shall not be deemed incorporated by reference into any other filing with the SEC made by the Company, whether made before or after today’s date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific…
Unregistered Sale of Equity Securities. As previously reported, Lyell Immunopharma, Inc., a Delaware corporation (“Lyell” or the “Company”), completed its acquisition (the “Merger”) of ImmPACT Bio USA Inc., a Delaware corporation (“ImmPACT”), pursuant to the Agreement and Plan of Merger (the “Merger Agreement”), dated as of October 24, 2024, by and among the Company, ImmPACT, Inspire Merger Sub Inc., a Delaware corporation, and WT Representative LLC, a Delaware limited liability company, as r…
Other Events. On June 17, 2025, Lyell Immunopharma, Inc. (the “Company”) announced new clinical data from its ongoing multi-center Phase 1/2 clinical trial of LYL314, including data from patients with large B-cell lymphoma (“LBCL”) treated in the third- or later-line (“3L+”) setting. LYL314 is an autologous dual-targeting CD19/CD20 chimeric antigen receptor (“CAR”) T-cell product candidate designed to increase complete response rates and prolong the duration of the responses as compared to ap…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2025, the Board of Directors (the “Board”) of Lyell Immunopharma, Inc. (the “Company”) increased the authorized size of the Board from seven directors to eight directors and, upon recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Mark Bachleda, Pharm.D., M.B.A., to the Board as a Class I director…
Material Modification to Rights of Security Holders. (a) On May 27, 2025, Lyell Immunopharma, Inc. (the “Company”) filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to effect a reverse stock split of its outstanding common stock at a ratio of 1-for-20 (the “Charter Amendment”). The Charter Amendment was authorized by the stockholders of the Company at the Company’s 2025 Annual Meeting of Stockholders…
Results of Operations and Financial Condition. On May 13, 2025, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or othe…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 27, 2025, Matthew Lang, J.D. notified the Company of his resignation as Chief Business Officer and from all other offices of the Company, effective April 13, 2025. Mr. Lang will remain as an advisor to the Company until September 30, 2025. Cautionary Note Regarding Forward-Looking Statements This Current Report on Form 8-K contains forward…
Costs Associated with Exit or Disposal Activities. Following a successful technology transfer and clearance by the U.S. Food and Drug Administration of an Investigational New Drug Comparability Protocol, Lyell Immunopharma, Inc.’s (the “Company” or “Lyell”) LyFE manufacturing center in Bothell, Washington is manufacturing IMPT-314 to supply the ongoing Phase 1/2 clinical trial for relapsed/refractory aggressive large B-cell lymphoma. Lyell expects the LyFE manufacturing center to have suffici…
Results of Operations and Financial Condition. On March 11, 2025, Lyell Immunopharma, Inc. (the “Company”) issued a press release announcing its financial results for the quarter and full year ended December 31, 2024. A copy of the press release is attached hereto as Exhibit 99.1. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exch…
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On January 23, 2025, Lyell Immunopharma, Inc. (the “Company”) received notice (the “Notice”) from the Listing Qualifications Staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the last 33 consecutive business days, the bid price of the Company’s common stock had closed below $1.00 per share, the minimum closing bid price required by the continued listing requiremen…
General market headlines, full earnings-call transcripts, and macro and sector developments flagged when they directly affect this stock are on the way. Today this tab covers SEC filings.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.